[關鍵詞]
[摘要]
目的 探討烏靈膠囊聯合氟伏沙明治療抑郁癥的臨床療效。方法 選取2023年3月—2023年8月北京市懷柔安佳醫(yī)院門診收治的97例抑郁癥患者,按隨機數字表法分為對照組(48例)和治療組(49例)。對照組睡前口服馬來酸氟伏沙明片,100 mg/次,1次/d。治療組在對照組治療基礎上口服烏靈膠囊,3粒/次,3次/d。兩組療程均為6周。觀察兩組的臨床療效,比較各時間點(即治療前和治療2、4、6周)17項漢密爾頓抑郁量表(HAMD-17)評分及治療前后9項患者健康問卷(PHQ-9)、阿森斯失眠量表(AIS)等量表評分和血清腦源性神經營養(yǎng)因子(BDNF)、白細胞介素-18(IL-18)、細胞間黏附分子-1(ICAM-1)等指標水平。結果 治療后,治療組患者總有效率是95.92%,顯著高于對照組的81.25%(P<0.05)。治療2、4、6周,兩組HAMD-17評分都小于同組治療前(P<0.05);治療2、4、6周治療組HAMD-17評分小于對照組同期(P<0.05)。治療后,兩組PHQ-9、DASS-21、AIS評分都小于同組治療前,而SF-36評分高于治療前(P<0.05);治療后,治療組PHQ-9、DASS-21、AIS、SF-36評分改善情況優(yōu)于對照組(P<0.05)。治療后,兩組血清BDNF水平都顯著上升,血清IL-18、ICAM-1水平顯著降低(P<0.05);治療后,治療組患者血清BDNF、IL-18、ICAM-1水平改善優(yōu)于對照組(P<0.05)。結論 烏靈膠囊聯合氟伏沙明能有效提高抑郁癥患者的臨床療效,降低機體炎癥反應與神經元功能損傷,促進抑郁、焦慮等不良情緒體驗緩解,改善睡眠情況和生活質量。
[Key word]
[Abstract]
Objective To explore the clinical efficacy of Wuling Capsules combined with fluvoxamine in treatment of depression. Methods A total of 97 patients with depression admitted to the Outpatient Department of Beijing Huairou Anjia Hospital from March 2023 to August 2023 were selected and divided into control group (48 cases) and treatment group (49 cases) according to random number table method. Patients in the control group were po administered with Fluvoxamine Maleate Tablets before going to bed, 100 mg/time, once daily. Patients in the treatment group were po administered with Wuling Capsules on the basis of the control group, 3 capsules/time, 3 times daily. The treatment course of both groups was 6 weeks. The clinical efficacy of the two groups was observed. 17 Hamilton Depression Scale (HAMD-17) scores at each time point (before treatment and 2, 4, and 6 weeks after treatment), 9 Patient Health Questionnaire (PHQ-9) and Asens Insomnia Scale (AIS) scores, serum levels of brain-derived neurotrophic factor (BDNF), Interleukin-18 (IL-18), and intercellular adhesion molecule-1 (ICAM-1) in two groups before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was 95.92%, which was significantly higher than that of the control group (81.25%, P < 0.05). After 2, 4 and 6 weeks of treatment, HAMD-17 scores in both groups were lower than before treatment (P < 0.05). The HAMD-17 score of the treatment group was lower than that of the control group after 2, 4 and 6 weeks of treatment (P < 0.05). After treatment, PHQ-9, DASS-21 and AIS scores in both groups were lower than before, but SF-36 scores were higher than before (P < 0.05). After treatment: the improvement of PHQ-9, DASS-21, AIS and SF-36 scores in the treatment group was better than that in the control group (P < 0.05). After treatment, serum BDNF levels were significantly increased in both groups, but serum IL-18 and ICAM-1 levels were significantly decreased (P < 0.05). After treatment, the serum levels of BDNF, IL-18 and ICAM-1 in the treatment group were better than those in the control group (P < 0.05). Conclusion Wuling Capsules combined with fluvoxamine can effectively improve the clinical efficacy of patients with depression, reduce inflammation and neuronal function damage, promote depression, anxiety and other adverse emotional experience relief, which can improve sleep and quality of life.
[中圖分類號]
R971
[基金項目]
北京懷柔安佳醫(yī)院科學技術研究與開發(fā)項目(BF-2022-36)